Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 11/20 | 0.40 |
| ▸ | ANPEP | P15144 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12480680 | 1.00 | MMP2 (0.40) | MMP2ANPEPALDH1A1POLBNR1H2 | |
| SCHEMBL7727315 | 0.86 | BTK (0.46) | MMP2ANPEPALDH1A1NR1H2NR1H3 | |
| SCHEMBL7731684 | 0.86 | BTK (0.46) | MMP2ANPEPALDH1A1NR1H2NR1H3 | |
| SCHEMBL7727313 | 0.86 | BTK (0.46) | MMP2ANPEPALDH1A1NR1H2NR1H3 | |
| SCHEMBL3894190 | 0.84 | MMP2 (0.38) | MMP2ANPEPALDH1A1POLBNR1H2 | |
| SCHEMBL14090197 | 0.84 | MMP2 (0.38) | MMP2ANPEPALDH1A1POLBNR1H2 | |
| SCHEMBL13938227 | 0.81 | MMP2 (0.47) | MMP2ANPEPALDH1A1POLBNR1H2 | |
| SCHEMBL13938226 | 0.81 | MMP2 (0.47) | MMP2ANPEPALDH1A1POLBNR1H2 | |
| SCHEMBL24538203 | 0.81 | MMP2 (0.49) | MMP2ALDH1A1POLBCYP1A2CYP3A4 | |
| SCHEMBL9006101 | 0.81 | MMP2 (0.49) | MMP2ALDH1A1POLBCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | MMP2 82/4885ANPEP 86/4885ALDH1A1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.